< Back to previous page
Researcher
Fred Van Leuven
- Disciplines:Genetics, Systems biology, Medical imaging and therapy, Molecular and cell biology, Other paramedical sciences
Affiliations
- Department of Human Genetics (Department)
Member
From1 Oct 1999 → 30 Sep 2014
Projects
1 - 9 of 9
- Influence of chronic oligemia on neurovascular defects and their relation to the onset and development of neurodegeneration: in vivo evaluation of neurovascular response capacity and metabolism in an Alzheimer mouse model.From1 Oct 2013 → 17 Sep 2019Funding: FWO fellowships
- Mechanisms underlying protein tau-mediated neurodegeneration: combining transgenic mouse models and AAV vectors.From1 Oct 2010 → 30 Sep 2014Funding: BOF - Concerted Research Project from 1994
- Differential analysis of the physiological functions of GSK-3a/b isozymes in brain in vivo.From1 Oct 2009 → 30 Jun 2010Funding: BOF - Other initiatives
- Development and validation of active and passive immunotherapy targeted at protein Tau in transgenic mouse models for Alzheimer's diseaseFrom1 Oct 2008 → 13 Sep 2013Funding: Own budget, for example: patrimony, inscription fees, gifts
- Tau-based Mabs and Vaccines: development and pre-clinical assessment of diagnostic and therapeutic potential in transgenic models for Tauopathy & Alzheimer's disease.From1 Oct 2008 → 30 Sep 2012Funding: IOF - Industrial Research Fund
- NEURO.GSK3: GSK3 in neuronal plasticity and neurodegeneration: basic mechanisms and pre-clinical assessment.From1 Oct 2008 → 31 Dec 2011Funding: Health
- The physiological and pathological contribution of GSK3 isozymes in normal mice and transgenic Alzheimer mice models.From1 Sep 2008 → 1 Jan 2010Funding: Own budget, for example: patrimony, inscription fees, gifts
- Inter-relations of protein Tau, GSK3 and Nectin-3 in synaptic structure and plasticity in the hippocampus of mouse models for Alzheimer's diseaseFrom1 Feb 2008 → 28 Jun 2013Funding: Own budget, for example: patrimony, inscription fees, gifts
- Analysis of adaptations of cytoskeleton, dendritic spines and synaptic plasticity in relation to physiological and pathological phosphorylation of protein tau in vivo.From1 Jan 2008 → 31 Dec 2011Funding: FWO research project
Publications
41 - 50 of 86
- Identification of Glycogen Synthase Kinase-3 Inhibitors with a Selective Sting for Glycogen Synthase Kinase-3 alpha(2012)
Authors: Fred Van Leuven
Pages: 4407 - 4424 - Isoflurane anesthesia precipitates tauopathy and upper airways dysfunction in pre-symptomatic Tau.P301L mice: Possible implication for neurodegenerative diseases(2012)
Authors: Fred Van Leuven
Pages: 234 - 243 - Protein tau: prime cause of synaptic and neuronal degeneration in Alzheimer's disease(2012)
Authors: Fred Van Leuven
Pages: 1 - 13 - Role of presenilin1 in structural plasticity of cortical dendritic spines in vivo(2011)
Authors: Fred Van Leuven
Pages: 1064 - 1073 - Synaptic dysfunction in hippocampus of transgenic mouse models of Alzheimer's disease: A multi-electrode array study(2011)
Authors: Bart De Strooper, Carmen Bartic, Fred Van Leuven, Geert Callewaert
Pages: 284 - 291 - GSK-3 alpha/beta kinases and amyloid production in vivo(2011)
Authors: Maarten Gees, Fred Van Leuven
Pages: E4 - E5 - Cognitive abilities of Alzheimer's disease transgenic mice are modulated by social context and circadian rhythm(2011)
Authors: Fred Van Leuven
Pages: 883 - 892 - Early improved and late defective cognition is reflected by dendritic spines in Tau.P301L mice(2011)
Authors: Fred Van Leuven
Pages: 18036 - 18047 - Dendritic degeneration, neurovascular defects, and inflammation precede neuronal loss in a mouse model for tau-mediated neurodegeneration(2011)
Authors: Fred Van Leuven
Pages: 2001 - 2015 - Raphé tauopathy alters serotonin metabolism and breathing activity in terminal Tau.P301L mice: possible implications for tauopathies and Alzheimer's disease(2011)
Authors: Fred Van Leuven
Pages: 290 - 303
Patents
1 - 10 of 10
- Humanized tau antibody (Inventor)
- Pharmaceutical composition (Inventor)
- Methods of diagnosing diseases caused by or associated with neurofibrillary tangles by phosphospecific antibodies recognising tau (Inventor)
- Antibodies to phosphorylated tau aggregates (Inventor)
- Phosphospecific antibodies recognising tau (Inventor)
- Methods of diagnosing tau-protein-associated disease (Inventor)
- Phosphospecific antibodies recognising tau (Inventor)
- ANTIBODIES RECOGNISING PHOSPHO-TAU (Inventor)
- Pharmaceutical composition (Inventor)
- Phosphospecific antibodies recognising tau (Inventor)